Amicus Therapeutics
FOLD
FOLD was delisted on the 24th of April, 2026.
68 hedge funds and large institutions have $71M invested in Amicus Therapeutics in 2014 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 17 increasing their positions, 27 reducing their positions, and 7 closing their positions.
268% more call options, than puts
Call options by funds: $140K | Put options by funds: $38K
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
1% less funds holding
Funds holding: 69 → 68 (-1)
12% less capital invested
Capital invested by funds: $81.1M → $71M (-$10M)
37% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$2.42M |
| 2 |
SGAM
Smith Group Asset Management
Dallas,
Texas
|
+$669K |
| 3 |
TI
Turner Investments
Berwyn,
Pennsylvania
|
+$632K |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$260K |
| 5 |
D.E. Shaw & Co
New York
|
+$134K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$1.14M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$795K |
| 3 |
Renaissance Technologies
New York
|
-$696K |
| 4 |
IHM
Iguana Healthcare Management
New York
|
-$623K |
| 5 |
RG
Redmile Group
San Francisco,
California
|
-$379K |
FOLD Hedge Fund Activity: Q1 2014 in Review
68 of the 3,464 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q1 2014, worth a combined $71M — down 12% from $81.1M a quarter earlier.
Fund positioning in FOLD was balanced in Q1 2014: 7 funds opened new positions, 7 closed out, 17 added to existing stakes and 27 trimmed.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $2.42M. The largest seller was TFS Capital, cutting an estimated $1.14M.
- 68 institutional investors held Amicus Therapeutics (FOLD) as of Q1 2014, down from 69 in Q4 2013.
- Funds reported $71M of Amicus Therapeutics stock for Q1 2014, down 12% quarter-over-quarter.
- 7 funds opened new Amicus Therapeutics positions in Q1 2014 and 7 closed out, a net change of 0 holders.
- The largest Amicus Therapeutics buyer in Q1 2014 was Perceptive Advisors, an estimated $2.42M added.
- The largest Amicus Therapeutics seller in Q1 2014 was TFS Capital, an estimated $1.14M sold.
Based on aggregated 13F filings for Q1 2014.